Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2010
10/26/2010CA2327349C Il-2 selective agonists and antagonists
10/26/2010CA2326501C Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
10/26/2010CA2319211C Recombinant proteins derived from hgf and msp
10/26/2010CA2291138C Transplants for myocardial scars and method and cellular preparations therefor
10/26/2010CA2284733C Motilin homologs
10/26/2010CA2133323C Self-assembling polynucleotide delivery system
10/21/2010WO2010121247A1 Agr-mediated inhibition of methicillin resistant staphylococcus aureus
10/21/2010WO2010121207A1 Methods and compositions related to the interaction of t-cadherin and adiponectin
10/21/2010WO2010121195A2 Methods of inhibiting adverse cardiac events and treating atherosclerosis and coronary artery disease using galectin-3 binding protein (gal-3bp, btbd17b, mac-2 binding protein)
10/21/2010WO2010121180A1 Combination immunotherapy compositions against cancer and methods
10/21/2010WO2010121125A1 Il-13 receptor binding peptides
10/21/2010WO2010121023A2 Peptides and aptamers for targeting of neuron or nerves
10/21/2010WO2010120931A2 E2f as a target for treatment of hormone refractory prostate cancer
10/21/2010WO2010120897A1 Compositions and methods for modulating immunogenic responses by activating dendritic cells
10/21/2010WO2010120838A1 Treating blurred vision and other conditions of the eye with cyclosporin composition
10/21/2010WO2010120830A1 Novel peptide-based scaffolds for cartilage regeneration and methods for their use
10/21/2010WO2010120691A2 Methionine sulfoxide peptide, compositions and methods of use
10/21/2010WO2010120566A2 METHODS FOR TREATING IgE-MEDIATED DISORDER
10/21/2010WO2010120541A2 Compositions and methods for modulating the activity of complement regulatory proteins on target cells
10/21/2010WO2010120514A2 Antigen-binding proteins comprising recombinant protein scaffolds
10/21/2010WO2010120509A2 Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
10/21/2010WO2010120476A2 N-terminus conformationally constrained glp-1 receptor agonist compounds
10/21/2010WO2010120431A2 Methods for the prevention and treatment of burn injuries and secondary complications
10/21/2010WO2010120374A2 Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
10/21/2010WO2010120365A2 Protein-carrier conjugates
10/21/2010WO2010120121A2 Target-specific non-antibody protein and method for preparing the same
10/21/2010WO2010119864A1 Peptide derivative
10/21/2010WO2010119804A1 Anti-mental fatigue agent
10/21/2010WO2010119803A1 Lipid metabolism-improving agent
10/21/2010WO2010119583A1 Polymer-nucleic acid complex, method for imaging tumor cells or the like using same, and pharmaceutical composition for treatment of cancer
10/21/2010WO2010119420A1 3d matrices of human elastin-like polypeptides and method of preparation thereof
10/21/2010WO2010119192A1 Cosmetic and/or pharmaceutical composition comprising a relieving peptidic hydrolysate
10/21/2010WO2010119191A1 Cosmetic and/or pharmaceutical composition comprising a peptidic hydrolysate that can reinforce the barrier function
10/21/2010WO2010119036A1 Novel post-translational fibrinogen variants
10/21/2010WO2010119021A1 Tenascin-w and brain cancers
10/21/2010WO2010118878A1 Muscle function enhancing peptide
10/21/2010WO2010118832A2 Inhibition of the liver enriched protein foxa2 for the treatment of colorectal liver metastases
10/21/2010WO2010118524A1 Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof
10/21/2010WO2010118521A1 Peptide ligands for clusterin and uses thereof
10/21/2010WO2010118516A1 Compositions for sublingual drug delivery and methods of use thereof
10/21/2010WO2010100428A3 Protein kinase a and/or casein kinase ii for alleviating the inhibition of neurite outgrowth
10/21/2010WO2010099139A3 Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor
10/21/2010WO2010097788A3 Visfatin therapeutic agents for the treatment of acne and other conditions
10/21/2010WO2010096173A3 Identification of extracellular form of pten that can be used to treat tumors
10/21/2010WO2010094734A3 Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
10/21/2010WO2010093731A3 Compositions, methods and uses for disease diagnosis
10/21/2010WO2010077364A3 Stroke-generated angiogenesis enhancers and uses thereof
10/21/2010WO2010048125A3 Compositions and methods for inhibiting the interaction between cftr and cal
10/21/2010WO2009136297A3 Fusion polypeptides comprising glycosylated mucin for inhibiting toxin a from clostridium difficile
10/21/2010WO2009068708A8 Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
10/21/2010WO2008122434A8 Bis-met histones
10/21/2010US20100269184 Apo-2DcR
10/21/2010US20100269180 Methods, compositions and transgenic models related to the interaction of t-cadherin and adiponectin
10/21/2010US20100268336 Materials and Method for Promotion of Nerve Regeneration
10/21/2010US20100268329 Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease
10/21/2010US20100268288 Electrical devices and anti-scarring agents
10/21/2010US20100267946 Prodrugs of gaba analogs, compositions and uses thereof
10/21/2010US20100267936 PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES
10/21/2010US20100267931 Heterologous expression of neisserial proteins
10/21/2010US20100267808 Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same
10/21/2010US20100267799 Orodispersible pharmaceutical composition of perindopril
10/21/2010US20100267651 T cell antigen receptor peptides
10/21/2010US20100267650 Dual Chain Synthetic Heparin-Binding Growth Factor Analogs
10/21/2010US20100267649 Vascular adhesion molecules and modulation of their function
10/21/2010US20100267648 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
10/21/2010US20100267647 Modulating photoreactivity in a cell
10/21/2010US20100267646 Trophic Factor for the Treatment of Retinal Degenerative Diseases
10/21/2010US20100267645 Methods and compositions for treating ocular disease
10/21/2010US20100267644 Cystatin C as an Antagonist of TGF-BETA and Methods Related Thereto
10/21/2010US20100267643 Chemosensory Receptor Ligand-Based Therapies
10/21/2010US20100267642 Use of complex forms of calmodulin-like skin protein clsp
10/21/2010US20100267641 Prognostic tests for development of dermal stretch marks and implications for the preventative treatment thereof
10/21/2010US20100267640 Method of Attenuating Neurogenic Swelling or Neurogenic Inflammation
10/21/2010US20100267639 Treatment of osteoarthritis
10/21/2010US20100267638 Exosite-directed thrombin inhibitors
10/21/2010US20100267637 Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
10/21/2010US20100267636 Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
10/21/2010US20100267635 Use of protease inhibitors and grf molecules in combination therapy
10/21/2010US20100267634 Anti-Viral Compounds
10/21/2010US20100267633 N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators
10/21/2010US20100267632 Treatment of neurodegenerative disorders
10/21/2010US20100267631 Apolipoprotein a-i mimics
10/21/2010US20100267630 Use of leptin in the prevention of unhealthy food habits and cardiovascular diseases
10/21/2010US20100267629 Enterostatin as Therapeutic Agent for Hypoglycemia
10/21/2010US20100267628 Analogs of Gastric Inhibitory Polypeptide and Their Use for Treatment of Diabetes
10/21/2010US20100267627 Support for protein transfer, protein transfer agent using the support, protein transfer method, cell having protein transferred thereinto and method of producing the same
10/21/2010US20100267626 Methods and compositions for measuring wnt activation and for treating wnt-related cancers
10/21/2010US20100267624 Vancomycin and teicoplanin anhydrous formulations for topical use
10/21/2010US20100267623 Peptides with capacity to bind to scurfin and applications
10/21/2010US20100267622 Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease
10/21/2010US20100267621 Antimicrobial Compounds and Formulations
10/21/2010US20100267620 Methods for slowing senescence and treating and preventing diseases associated with senescence
10/21/2010US20100267619 Methods and Compositions for Treatment of Atherosclerosis
10/21/2010US20100267618 Methods for treating congestive heart failure
10/21/2010US20100267617 Methods and compositions for mycoplasma pneumoniae exotoxins
10/21/2010US20100267616 Acute respiratory syndromes
10/21/2010US20100267615 Methods for treatment and/or prevention of a disease associated with vascular leak
10/21/2010US20100267614 Prodrugs of Peripheral Phenolic Opioid Antagonists
10/21/2010US20100267613 Hypoallergenic cereal protein and uses thereof
10/21/2010US20100267612 Sustained release composition containing sdf-1
1 ... 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 ... 3163